61 to 69 of 69 Results
Adobe PDF - 625.1 KB -
MD5: 591d49eda306f69d5fd24a059d714ccc
Suppl. Table 1. Checklist according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monoth... |
Adobe PDF - 363.9 KB -
MD5: 7c1640658f8d06736e3dad712a927841
Suppl. Table 2. Search strategies for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors. |
MS Excel Spreadsheet - 116.7 KB -
MD5: 7b97c14d958dffb9cb3347b48fd10fba
Suppl. Table 3. Study characteristics of randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors. NSCLC, Non-small cell lung cancer; LD-SCLC, Limited... |
Adobe PDF - 257.8 KB -
MD5: d6acaa2141ff4cf50ded0d6820579aea
Suppl. Table 4. Frequencies of various parameters in included trials, n= 80 trials. |
Adobe PDF - 220.6 KB -
MD5: 09b0b7b7245dcb116eb15df62fdef98d
Suppl. Table 5. Meta-regression for trials investigating hypothyroidism any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials. |
Adobe PDF - 220.7 KB -
MD5: 30371284a775d08e7044c09b78aaeace
Suppl. Table 6. Meta-regression for trials investigating hyperthyroidism any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials. |
Adobe PDF - 216.5 KB -
MD5: c1e3211bc08d5e1fd11cb1ca68248762
Suppl. Table 7. Trim-and-fill results for trials investigating hypophysitis/hypopituitarism any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials. |
Adobe PDF - 218.9 KB -
MD5: e32fa8cb72081403d574d4d1d280e827
Suppl. Table 8. Trim-and-fill results for trials investigating hypophysitis/hypopituitarism grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials. |
Adobe PDF - 216.7 KB -
MD5: 78f6d13d435b94fe3733e03fdaf77c63
Suppl. Table 9. Trim-and-fill results for trials investigating adrenal insufficiency any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials. |